What is the enterprise value (EV) for Pacific Biosciences of California, Inc. (PACB)?

The enterprise value (EV) for PACB stock is $1.47B.

Pacific Biosciences of California (PACB) Enterprise Value: History & Chart

Compare

Pacific Biosciences of California, Inc.(PACB)

Medical - Devices · Menlo Park, CA

$2.68-0.19 (-6.69%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Compare

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Menlo Park, CA

485 employees

www.pacb.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Mark Van Oene

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Pacific Biosciences of California, Inc. (PACB)	$831.79M	$1.47B
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$833.81M	$781.69M
SpyGlass Pharma, Inc. Common Stock (SGP)vs ›	$828.48M	$606.97M
Beta Bionics, Inc. (BBNX)vs ›	$838.16M	$800.35M
Ardelyx, Inc. (ARDX)vs ›	$817.67M	$976.66M
Jade Biosciences, Inc. (JBIO)vs ›	$816.13M	$709.51M
SL Science Holding Ltd (SLBT)vs ›	$852.35M	$851.31M
Rigel Pharmaceuticals, Inc. (RIGL)vs ›	$853.13M	$832.27M
Alumis Inc. (ALMS)vs ›	$855.38M	$828.11M
QuidelOrtho Corporation (QDEL)vs ›	$857.16M	$3.81B

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Pacific Biosciences of California, Inc. (PACB)

$831.79M

$1.47B

Monte Rosa Therapeutics, Inc. (GLUE)vs ›

$833.81M

$781.69M

SpyGlass Pharma, Inc. Common Stock (SGP)vs ›

$828.48M

$606.97M